1. Home
  2. FRME vs EVO Comparison

FRME vs EVO Comparison

Compare FRME & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Merchants Corporation

FRME

First Merchants Corporation

HOLD

Current Price

$40.27

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.06

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRME
EVO
Founded
1893
1993
Country
United States
Germany
Employees
2086
4553
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FRME
EVO
Price
$40.27
$3.06
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$48.33
$7.00
AVG Volume (30 Days)
260.3K
47.1K
Earning Date
04-22-2026
04-08-2026
Dividend Yield
3.62%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.67
$1.37
Revenue Next Year
$5.91
$10.05
P/E Ratio
$10.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.66
$2.31
52 Week High
$43.22
$4.42

Technical Indicators

Market Signals
Indicator
FRME
EVO
Relative Strength Index (RSI) 52.73 56.03
Support Level $38.74 $2.88
Resistance Level $41.82 $3.75
Average True Range (ATR) 0.79 0.07
MACD 0.05 0.01
Stochastic Oscillator 66.05 89.58

Price Performance

Historical Comparison
FRME
EVO

About FRME First Merchants Corporation

First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: